tiprankstipranks
Trending News
More News >

GSK, iTeos ending development program for belrestotug

GSK plc (GSK), with its development partner iTeos Therapeutics (ITOS), confirmed it is ending the development program for belrestotug, an anti-TIGIT monoclonal antibody. “The decision is based on new interim analyses from the phase 2 GALAXIES Lung-201 and GALAXIES H&N-202 studies, which did not meet the established efficacy criteria for continued development. As a result, the collaboration and all belrestotug-containing study cohorts are ending,” GSK stated.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue